We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Immunic Inc (IMUX) USD0.0001

Sell:$8.32 Buy:$8.34 Change: $0.29 (3.37%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
Change: $0.29 (3.37%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
Change: $0.29 (3.37%)
Market closed |  Prices as at close on 29 November 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Immunic, Inc., formerly Vital Therapies, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The Company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.

Contact details

Am Klopferspitz 19
+49 (89) 250079460

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$226.01 million
Shares in issue:
26.25 million
United States
US dollar

Key personnel

  • Duane Nash
    Executive Chairman of the Board
  • Daniel Vitt
    President, Chief Executive Officer, Director
  • Glenn Whaley
    Vice President - Finance, Principal Financial and Accounting Officer
  • Manfred Groppel
    Chief Operating Officer
  • Hella Kohlhof
    Chief Scientific Officer
  • Inderpal Singh
    General Counsel
  • Andreas Muehler
    Chief Medical Officer
  • Patrick Walsh
    Chief Business Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.